Newer treatment options for patients with moderate-to-severe psoriatic disease.

Heather L Roebuck

Journal: The Nurse practitioner 2006;31(8):5-6,11

PMID: 16966969

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Address: M. Siegel MD, P.C. Diseases-Surgery of the Skin, Waterford, MI, USA.

DOI: 10.1097/00006205-200608000-00002

Link outs

Free resources

Medical:

https://medlineplus.gov/psoriasis.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adalimumab, Alefacept, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Attitude to Health, Betamethasone, Body Image, Calcitriol, Clobetasol, Dermatologic Agents, Diagnosis, Differential, Drug Monitoring, Etanercept, Humans, Immunoglobulin G, Immunosuppressive Agents, Infliximab, Psoriasis, Receptors, Tumor Necrosis Factor, Recombinant Fusion Proteins, Severity of Illness Index

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.